Royal Bank of Canada lowered its stake in shares of CryoLife, Inc. (NYSE:CRY) by 19.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,934 shares of the medical equipment provider’s stock after selling 18,344 shares during the quarter. Royal Bank of Canada owned 0.23% of CryoLife worth $1,555,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Municipal Employees Retirement System of Michigan increased its position in shares of CryoLife by 3.2% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 190 shares during the period. State of Alaska Department of Revenue increased its position in shares of CryoLife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 2,407 shares during the period. First Mercantile Trust Co. increased its position in shares of CryoLife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 291 shares during the period. Creative Planning increased its position in shares of CryoLife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after acquiring an additional 200 shares during the period. Finally, Victory Capital Management Inc. increased its position in shares of CryoLife by 17.7% during the second quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock worth $138,000 after acquiring an additional 1,041 shares during the period. 69.01% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on CRY. Zacks Investment Research lowered CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Lake Street Capital upped their price objective on CryoLife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 price objective on shares of CryoLife in a research report on Monday, October 9th. Finally, BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. CryoLife has a consensus rating of “Hold” and an average target price of $23.63.
In other CryoLife news, Director James Benson sold 2,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $22.80, for a total value of $45,600.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. Insiders sold a total of 171,050 shares of company stock worth $3,769,825 in the last quarter. 6.00% of the stock is currently owned by company insiders.
WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/01/royal-bank-of-canada-sells-18344-shares-of-cryolife-inc-cry.html.
Shares of CryoLife, Inc. (CRY) opened at 19.45 on Wednesday. CryoLife, Inc. has a 52-week low of $14.02 and a 52-week high of $24.00. The stock’s 50 day moving average price is $21.66 and its 200-day moving average price is $19.61. The stock has a market cap of $650.52 million, a price-to-earnings ratio of 58.94 and a beta of 0.92.
CryoLife (NYSE:CRY) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.50%. The business had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same quarter in the previous year, the business posted $0.13 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. On average, analysts predict that CryoLife, Inc. will post $0.41 earnings per share for the current fiscal year.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.